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Abstract 
Purpose Afatinib, an irreversible ErbB family blocker, has demonstrated preclinical antitumor 
activity with chemotherapy.
Methods   As part of a phase I trial in patients with advanced solid tumors (NCT00809133; 3+3 
dose-escalation design), we determined the maximum tolerated dose (MTD) of afatinib with 
carboplatin (A/C) or with carboplatin plus paclitaxel (A/C/P). Starting doses: afatinib 20mg/day, 
carboplatin AUC6 (A/C); with paclitaxel 175mg/m2 (A/C/P) (chemotherapy: Day 1 of 21-day 
cycles). The primary objective was to determine the MTDs; safety, pharmacokinetics and 
antitumor activity were also evaluated. 
Results   Thirty-eight patients received A/C (n=12) or A/C/P (n=26). No dose-limiting toxicities 
(DLTs) were reported with A(20mg)/C(AUC6). One patient experienced DLT in the 
A(40mg)/C(AUC6) cohort (grade 3 acneiform rash); A(40mg)/C(AUC6) was determined as the 
recommended phase II dose (RP2D) for A/C. Two patients each had DLTs with 
A(20mg/day)/C(AUC6)/P(175mg/m2): fatigue, infection, diarrhea, small intestine hemorrhage, 
dehydration, renal impairment, neutropenic sepsis (n=1), mucositis (n=1); 
A(40mg)/C(AUC5)/P(175mg/m2): febrile neutropenia (n=1), mucositis, fatigue (n=1); and 
A(30mg)/C(AUC5)/P(175mg/m2): stomatitis (n=1), mucositis (n=1). No DLT was observed with 
A(20mg)/C(AUC5)/P(175mg/m2), determined as the RP2D for A/C/P. The most frequent drug-
related adverse events were (A/C; A/C/P): rash (75%; 73%), fatigue (67%; 69%), diarrhea (58%; 
88%). Drug plasma concentrations were similar between cycles, suggesting no drug–drug 
interactions. Objective response rates in these heavily pretreated patients were: A/C, 3/12 
(25%); A/C/P, 5/26 (19%). 
Conclusions Afatinib 40 mg/day (approved monotherapy dose) with carboplatin AUC6, and 
afatinib 20mg/day with carboplatin AUC5 and paclitaxel 175mg/m2, demonstrated manageable 
safety and antitumor activity. Afatinib >20mg/day in the triple combination was not well 
tolerated. 
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Introduction 
Afatinib is an irreversible ErbB family blocker, which binds covalently to the intracellular kinase 
domains of, and prevents signaling from, all kinase-active members of the ErbB family. It is 
therefore active against epidermal growth factor receptor (EGFR), human epidermal growth 
factor receptor 2 (HER2) and ErbB4, and indirectly inhibits transphosphorylation of the kinase-
inactive ErbB3 [1]. As a single agent, afatinib is approved for the first-line treatment of advanced 
EGFR mutation-positive lung adenocarcinoma, having demonstrated improved progression-free 
survival (PFS) versus platinum-based chemotherapy in these patients [2, 3]. In addition, afatinib 
was recently approved for the treatment of patients unselected for EGFR mutations with 
advanced squamous cell carcinoma of the lung following first-line chemotherapy, with activity 
superior to erlotinib in this setting [4]. 
Given their non-overlapping mechanisms of action, the addition of targeted therapies 
such as afatinib to existing chemotherapy regimens may improve outcomes in patients with 
advanced solid tumors. In vitro cell-based assays have shown greater efficacy with afatinib 
combined with paclitaxel than with single-agent treatment [5]. The combination of afatinib with 
paclitaxel or docetaxel in xenograft animal models has also demonstrated improved efficacy 
compared with single-agent therapy [6]. 
The clinical feasibility and tolerability of combining afatinib with paclitaxel, and with 
paclitaxel plus bevacizumab, were previously explored in earlier parts of this trial (a total of four 
drug combinations were assessed in patients with advanced solid tumors in this trial 
[NCT00809133]) [5, 7]. Both of these earlier combination regimens demonstrated manageable 
safety profiles and antitumor activity at the maximum tolerated doses (MTDs). Here, we 
evaluated the combination of afatinib with carboplatin, and with carboplatin and paclitaxel, in 
patients with advanced solid tumors. 
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Materials and methods 
Patients 
Patients eligible for treatment had advanced, non-resectable and/or metastatic solid tumors 
suitable for treatment with either carboplatin or carboplatin and paclitaxel, and were recruited at 
two centers in the United Kingdom. Key eligibility criteria included age ≥18 years; Eastern 
Cooperative Oncology Group performance status (ECOG PS) of 0 or 1; life expectancy of at 
least 3 months and adequate organ function (cardiac left ventricular function with resting 
ejection fraction [LVEF] ≥50%; absolute neutrophil count ≥1.5 x 109/L [>2.0 x 109/L for patients 
allocated to carboplatin]; platelets ≥100,000/µL; total bilirubin ≤26 µmol/L; aspartate 
aminotransferase and/or alanine aminotransferase ≤2.5 times the upper limit of normal; 
creatinine ≤132 µmol/L and creatinine clearance >60 mL/min by Cockcroft-Gault equation). 
Exclusion criteria included gastrointestinal tract disease that could impair drug 
absorption; significant cardiovascular disease; active infectious disease; known interstitial lung 
disease; untreated or symptomatic brain metastases; persistent grade ≥2 neuropathy or 
neurotoxicity from any cause; and treatment with chemotherapy, immunotherapy, radiotherapy, 
biologic therapy, hormone therapy, EGFR- or HER2-targeting drugs or other investigational 
drugs within 4 weeks prior to starting trial medication. 
The study was conducted in accordance with the Declaration of Helsinki and Good 
Clinical Practice, and ethical approval was provided by the UK Integrated Research Application 
System. All patients provided written informed consent. 
Study design and treatment 
A phase I open-label trial assessed four different drug combinations using a 3 + 3 dose-
escalation design (NCT00809133); previous analyses of other combination regimens included in 
the trial have been reported [5, 7]. In this report, afatinib was evaluated in combination with 
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carboplatin (A/C) or carboplatin plus paclitaxel (A/C/P). In both combinations, oral afatinib was 
administered once daily, beginning on Day 2 of Cycle 1 in 21-day cycles, at a starting dose of 
20 mg/day, and escalated to 40 mg (the approved monotherapy starting dose) and then 50 mg 
in subsequent dose cohorts. Chemotherapy was administered intravenously on Day 1 of each 
21-day cycle: carboplatin at a dose targeting an area under the concentration–time curve of 6 
mg/mL.min (AUC6), and paclitaxel at 175 mg/m2 (carboplatin was administered after paclitaxel, 
consistent with standard medical practice in the United Kingdom) [8]. Target doses for 
carboplatin were calculated using the Calvert formula (dose [mg] = target AUC [mg/mL.min] x 
(glomerular filtration rate [GFR; mL/min] + 25 mL/min)). Based on the American Society for 
Clinical Oncology guidelines, the GFR used in the Calvert formula was capped at 125 mL/min 
[9]. In the event of toxicity with carboplatin AUC6, a dose reduction to AUC5 was allowed. 
Patients continued combination treatment for six cycles or until tumor progression, intolerable 
adverse events (AEs) or withdrawal of consent. Patients with clinical benefit after six cycles 
could continue either with combination treatment or single-agent afatinib. 
The primary endpoint was safety, assessed as dose-limiting toxicities (DLTs) to define 
the MTD of the two afatinib–chemotherapy combinations. MTD was defined as the highest dose 
of afatinib in combination with carboplatin, or with carboplatin and paclitaxel, at which no more 
than one of six patients experienced a DLT during Cycle 1. To be evaluable for determination of 
the MTD, patients must have completed the first 2 weeks of therapy or have experienced a DLT; 
patients who did not meet either of these criteria were replaced within the respective dose 
cohort. Secondary endpoints included pharmacokinetic parameters and antitumor activity 
(objective tumor responses [OR]). 
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Assessments 
All patients were assessed for AEs according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0); relationship to study 
treatment was assessed by the investigators.  
DLTs were defined as any of the following drug-related AEs: grade 4 uncomplicated 
neutropenia (i.e., fever ≤38.3°C) for >7 days; neutropenia associated with fever >38.5°C; 
platelets <25 x 109/L or grade 3 thrombocytopenia associated with bleeding requiring 
transfusion; grade ≥2 decrease in LVEF; uncontrolled hypertension despite multiple anti-
hypertension therapies; grade ≥2 worsening of renal function; grade >2 diarrhea despite anti-
diarrheal treatment; persistent grade ≥2 diarrhea for ≥7 days despite supportive care; grade >2 
nausea and/or vomiting despite antiemetic treatment; persistent grade ≥2 vomiting for ≥7 days 
despite supportive care; and all other non-hematologic toxicities of grade ≥3, except 
incompletely treated nausea, vomiting or diarrhea. 
For the assessment of pharmacokinetic parameters of afatinib (AUCτ,ss and Cmax,ss), total 
platinum (AUC0–24 and Cmax) and paclitaxel (AUC0–23 and Cmax), blood was collected on Days 1 
and 2 of Cycles 1 and 2. Samples were taken pre- and post- (1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0 and 
24.0 h) carboplatin infusion (in the A/C arm) and pre- and post- (1.0, 2.0, 3.0, 3.5, 4.0, 4.5, 5.0, 
6.0, 8.0, 9.0 and 24.0 h) paclitaxel infusion (in the A/C/P arm). Of note, the 1.0- and 2.0-h time 
points post-paclitaxel infusion were conducted only during Cycle 2. A sample was also collected 
on Day 15 of Cycle 1 before the administration of afatinib in both treatment combinations. 
Plasma concentrations of afatinib and paclitaxel were analyzed by a validated high performance 
liquid chromatography-tandem mass spectrometry method at Boehringer Ingelheim (Biberach, 
Germany) and Nuvisan GmbH (Neu-Ulm, Germany), respectively. Concentrations of total 
platinum (from carboplatin) were determined by a validated inductively coupled plasma/mass 
spectrometry assay at Nuvisan GmbH (Neu-Ulm, Germany). 
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Tumor assessments were performed by the investigators at screening and every 6 
weeks after the start of treatment until progressive disease (PD) according to Response 
Evaluation Criteria in Solid Tumors (RECIST, version 1.0). 
Statistical analysis 
AEs and antitumor activity were assessed in all patients who received at least one dose of 
afatinib. All analyses in this trial were descriptive and exploratory. 
Results 
Patients and treatment exposure 
Thirty-eight patients were treated in the trial, with the most common tumor type (A/C, 58%; 
A/C/P, 65%) being non-small-cell lung cancer (NSCLC). Additional baseline demographics and 
disease characteristics are shown in Table 1. Twelve patients received the combination of A/C 
and 26 received A/C/P. In the A/C arm, 10 (83%) patients completed at least one cycle and six 
(50%) patients completed at least six cycles of treatment; all patients discontinued study 
treatment due to PD. In the A/C/P arm, 24 (92%) patients completed at least one cycle and 11 
(42%) patients completed at least six cycles of treatment. The primary reason for termination of 
study treatment in the A/C/P arm was PD in 21 patients (81%) and AEs, including DLTs, in five 
patients (19%). Median treatment duration was 106 days (range 13–390) for A/C and 85 days 
(range 6–401) for A/C/P. 
MTD assessment 
In the A/C arm, nine patients were evaluable for determination of MTD (Fig. 1a; Table 2). In 
Cohort 1 (afatinib 20 mg plus carboplatin AUC6), three patients received combination treatment 
and no DLTs were reported. In Cohort 2 (afatinib 40 mg plus carboplatin AUC6), no DLTs were 
reported in the first three evaluable patients (two patients were not evaluable for MTD 
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determination and were replaced), and the cohort was expanded to nine patients (one patient 
was not evaluable and was replaced). Of the six patients who were evaluable for MTD in Cohort 
2, one experienced a DLT (grade 3 acneiform rash). The afatinib dose, here combined with a 
dose of carboplatin, was not further escalated from the standard monotherapy dose of 40 mg, 
consistent with standard of care. Afatinib 40 mg plus carboplatin AUC6 was defined as the 
recommended phase II dose (RP2D) in the A/C arm, without an MTD being reached. 
In the A/C/P arm, 23 of 26 patients were evaluable for assessment of the MTD (Fig. 1b; 
Table 2). Of the seven patients who received treatment in Cohort 1 (afatinib 20 mg plus 
carboplatin AUC6 plus paclitaxel 175 mg/m2), six were evaluable for MTD and two had DLTs, 
which included grade 3 neutropenic sepsis with Clostridium difficile diarrhea in one patient and 
grade 3 mucositis in the other patient (Table 2). The carboplatin dose was decreased to AUC5 
in Cohort 2 (afatinib 20 mg plus carboplatin AUC5 plus paclitaxel 175 mg/m2), in which three 
patients received treatment and no DLTs were reported. The afatinib dose was then increased 
to 40 mg in Cohort 3 (afatinib 40 mg plus carboplatin AUC5 plus paclitaxel 175 mg/m2), and five 
patients received treatment and were evaluable for MTD; two patients had DLTs (grade 3 
fatigue and grade 3 mucositis in one patient; grade 3 febrile neutropenia in another). Owing to 
the DLTs observed, an intermediate afatinib dose of 30 mg was explored in Cohort 4 (afatinib 
30 mg plus carboplatin AUC5 plus paclitaxel 175 mg/m2). Eight patients received this treatment 
and, of the six patients evaluable for MTD, two reported DLTs (grade 3 stomatitis; grade 3 
mucositis). The next lower dose level (afatinib 20 mg plus carboplatin AUC5 plus paclitaxel 175 
mg/m2) was then expanded with three patients, in addition to the three patients already treated 
with these doses in Cohort 2, and no DLTs were reported. Thus, afatinib 20 mg was identified 
as the MTD in combination with carboplatin AUC5 and paclitaxel 175 mg/m2. This dose was 
also identified as the RP2D for the A/C/P combination. 
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Adverse events 
The most frequent drug-related AEs of any grade in the A/C arm were rash (grouped term; n=9, 
75%), which was most commonly acneiform, fatigue (n=8, 67%) and diarrhea (n=7, 58%). Most 
AEs were of CTCAE grade 1 or 2 in intensity (Table 3), and the only non-hematologic treatment-
related grade 3 AEs in this arm were rash, fatigue and diarrhea (one patient each; 8%). There 
were no treatment-related grade ≥4 AEs. 
The most frequent drug-related AEs in the A/C/P arm were diarrhea (n=23, 88%), rash 
(grouped term; n=19, 73%) and fatigue (n=18, 69%). Most AEs were of CTCAE grade 1 or 2 in 
intensity, and there were no grade ≥4 treatment-related AEs (Table 4). The most common non-
hematologic treatment-related grade 3 AEs in this arm were mucositis (n=4; 15%) and fatigue 
(n=3; 12%). Seven (27%) patients, including one patient with Clostridium difficile infection and 
one patient with mucositis (discussed above as DLTs), had AEs leading to discontinuation of 
study treatment. 
Pharmacokinetics 
Table 5 summarizes key pharmacokinetic parameters for the RP2D cohorts of both treatment 
arms. Total platinum and paclitaxel showed a comparable exposure, based on Cmax and AUC, in 
the absence and presence of afatinib, suggesting no clinically relevant effect of afatinib on the 
pharmacokinetic parameters of these drugs. Afatinib reached peak plasma concentration 1–4 h 
after administration in the A/C arm and 3–8 h after administration in the A/C/P arm. 
Antitumor activity 
In the A/C arm, three patients (25%) had a confirmed partial response (PR), five (42%) had 
stable disease (SD) and one (8%) had PD; three patients (25%) were not evaluable for tumor 
response. Five patients (42%) achieved disease control (PR or SD) for at least 6 months. No 
ORs were seen in the seven patients with NSCLC receiving A/C treatment, but four patients 
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(57%) had a best response of SD, one (14%) for at least 6 months. A response duration of 10.2 
months was seen in one patient with a gastrointestinal neuroendocrine tumor.  
In the A/C/P arm, five patients (19%) had a confirmed PR, 11 (42%) had SD and six 
(23%) had PD; four patients (15%) were not evaluable for tumor response. Of the 17 patients 
with NSCLC treated with A/C/P, ORs were reported for three patients (18%), and eight (47%) 
had SD. Four patients (15%), all of whom had NSCLC, achieved disease control (PR or SD) for 
at least 6 months. A response duration of 10.5 months was seen in one patient with NSCLC. 
Discussion 
In this phase I study we assessed the safety and preliminary antitumor activity of afatinib in 
combination with carboplatin, and with carboplatin plus paclitaxel. In the A/C arm, dose 
escalation was not continued beyond afatinib 40 mg/day plus carboplatin AUC6 and so an MTD 
was not reached. The standard dose for afatinib monotherapy is 40 mg/day [10, 11]. Since 
manageable safety and antitumor activity were observed at this dose level with carboplatin 
AUC6, and no drug–drug interactions were observed, the RP2D was determined as afatinib 40 
mg plus carboplatin AUC6. In the A/C/P arm, the MTD and RP2D were determined to be 
afatinib 20 mg plus carboplatin AUC5 plus paclitaxel 175 mg/m2. For this triplet combination, the 
afatinib single-agent dose needed to be de-escalated (from 40 to 20 mg) in order for the 
regimen to be tolerated. In both treatment combinations, afatinib at the RP2D was associated 
with a manageable safety profile. The most common drug-related AEs were rash, fatigue and 
diarrhea, and the majority of these were grade 1 or 2 in intensity. The AE profiles of the 
combinations were in line with the known individual safety profiles of afatinib, carboplatin and 
paclitaxel [5, 10‒12]. 
Afatinib pharmacokinetic parameters were consistent with earlier studies of afatinib as a 
single agent [13, 14] and in combination [7], suggesting carboplatin and paclitaxel did not 
influence absorption and plasma concentrations of afatinib. Similarly, total platinum (from 
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carboplatin) and paclitaxel plasma concentrations were similar in the absence and presence of 
afatinib, suggesting there were no relevant interactions between afatinib and paclitaxel and/or 
carboplatin in this study.  
Evidence of antitumor activity was observed with both the A/C and A/C/P combinations. 
A/C was associated with disease control (PR or SD) in eight patients (67%), while disease 
control was observed in 16 patients (62%) receiving A/C/P. In this study, 58% and 65% of 
patients in the A/C and A/C/P arms, respectively, had NSCLC. Of these pretreated NSCLC 
patients, more than half in each treatment combination had disease control (57% in the A/C arm 
and 65% in the A/C/P arm), with 18% achieving an OR in the A/C/P arm. Of note, a response in 
one patient with NSCLC in the A/C/P combination arm was maintained for 10.5 months.  
Several randomized trials have evaluated the potential clinical activity of the combination 
of EGFR-targeted agents with chemotherapy in advanced cancers, particularly NSCLC. Phase 
III studies in the first-line NSCLC setting in populations unselected for EGFR mutation have 
shown varying degrees of clinical efficacy for EGFR-targeted agent–chemotherapy 
combinations versus chemotherapy alone [15‒17]. In the phase III TRIBUTE trial, 1059 
treatment-naïve patients with NSCLC were randomized to first-line carboplatin and paclitaxel 
combined with either erlotinib or placebo. No survival benefit was observed with erlotinib plus 
chemotherapy versus placebo plus chemotherapy in the overall trial population; however, a 
substantial prolongation of survival was observed in the ‘never smoked’ subgroup (22.5 vs. 10.1 
months; hazard ratio [HR] 0.49, 95% confidence interval [CI] 0.28–0.85; p=0.01) [15]. Similarly, 
in the phase III TALENT trial, 1172 treatment-naïve patients with NSCLC were randomized to 
first-line gemcitabine and cisplatin combined with either erlotinib or placebo, with no survival 
benefit observed in the erlotinib group. In a small subgroup of patients who ‘never smoked’, 
overall survival (OS) and PFS were increased with chemotherapy and erlotinib, compared to 
chemotherapy alone [17]. In contrast to the TALENT and TRIBUTE studies, the phase III FAST-
ACT2 trial, conducted primarily in Asia, demonstrated significantly improved PFS (HR 0.57, 95% 
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CI 0.47–0.69; p<0.0001) and OS (HR 0.79, 95% CI 0.64–0.99; p=0.0420) with first-line 
chemotherapy (gemcitabine and platinum; Days 1 and 8 of a 4-week cycle) plus erlotinib (Days 
15–28 of each cycle) over chemotherapy alone in 451 treatment-naïve patients with NSCLC. 
Benefit was primarily shown in those with EGFR mutation-positive disease; however, tumor 
samples were available in only 53% of the intent-to-treat population [16]. 
The combination of EGFR-targeted agents with chemotherapy has also been explored in 
the relapsed/refractory NSCLC setting. A randomized, phase II study in 165 patients with non-
squamous NSCLC previously treated with one prior platinum-based chemotherapy regimen 
showed that pemetrexed plus erlotinib significantly improved PFS, OS and time to treatment 
failure versus pemetrexed alone; however, the combination was associated with an increase in 
grade 3/4 AEs [18]. We have previously reported on the combination of afatinib and weekly 
paclitaxel in patients with advanced solid tumors [5]. This regimen has since been assessed in a 
phase III trial of patients with relapsed/refractory NSCLC following ≥1 line of chemotherapy, and 
whose tumors had progressed after disease control of ≥12 weeks with erlotinib or gefitinib, and 
thereafter, afatinib. The combination of afatinib with paclitaxel significantly improved tumor 
response and PFS compared with paclitaxel alone in patients who had EGFR tyrosine kinase 
inhibitor (TKI)-resistant (including afatinib) disease [19]. Conversely, in the phase III IMPRESS 
study, gefitinib plus cisplatin and pemetrexed in patients with EGFR mutation-positive advanced 
NSCLC and acquired resistance to first-line gefitinib did not prolong PFS in the overall 
population versus cisplatin plus pemetrexed [20]. Indeed, OS was inferior in the experimental 
arm of this trial, although there was a suggestion of improved outcomes in patients lacking the 
T790M resistance mutation [21]. 
In the current study, the safety and clinical activity of two new afatinib combinations in 
patients with advanced solid tumors are presented. The RP2Ds of oral afatinib in these new 
combinations were defined as 40 mg/day with carboplatin AUC6, and 20 mg/day with 
carboplatin AUC5 and paclitaxel 175 mg/m2. These regimens may be of potential interest for 
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further study, for example: in patients with squamous NSCLC; in selected populations with 
EGFR mutations; and particularly the combination of afatinib and carboplatin, in elderly 
populations and patients with an ECOG PS of ≥2. 
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Tables 
Table 1 Patient demographics at baseline 
A/C 
(n=12) 
A/C/P 
(n=26) 
Age, years 
Median (range) 57.5 (35–80) 60.5 (26–73) 
Gender, n (%) 
Male  
Female 
8 (67) 
4 (33) 
13 (50) 
13 (50) 
Race, n (%) 
White 
Black 
Asian 
8 (67) 
2 (17) 
2 (17) 
23 (88) 
1 (4) 
2 (8) 
ECOG PS, n (%)  
0 
1 
2 
0 
12 (100) 
0 
2 (8) 
23 (88) 
1 (4)a
Time from first histologic diagnosis, years 
Median (range) 1.5 (0.7–6.3) 1.9 (0.7–6.6) 
19 
Tumor type, n (%) 
NSCLC 
Pancreas 
Gastrointestinal tract 
Breast 
Otherb
7 (58) 
1 (8) 
2 (17) 
0 
2 (17) 
17 (65) 
3 (12) 
0 
2 (8) 
4 (15) 
Patients with previous anti-cancer therapy, n (%) 
Surgery 
Systemic chemotherapy 
Immunotherapy 
Hormone therapy 
Radiotherapy 
Other (including biologic therapy) 
5 (42) 
12 (100) 
1 (8) 
0 (0) 
6 (50) 
7 (58) 
11 (42) 
26 (100) 
1 (4) 
1 (4) 
13 (50) 
6 (23) 
A/C afatinib plus carboplatin; A/C/P afatinib plus carboplatin plus paclitaxel; ECOG PS Eastern 
Cooperative Oncology Group performance status; NSCLC non-small-cell lung cancer 
a ECOG PS declined between screening and baseline; baseline visit was 2 days after the screening visit 
for this patient 
b Esophageal (n=1) and ovarian cancer (n=1) in the A/C arm; adrenal (n=1), biliary tree (n=1), bladder 
(n=1) and endometrial cancer (n=1) in the A/C/P arm 
20 
Table 2 DLTs (related to study drug) in Cycle 1 by dose cohort 
A/C  A/C/P 
A (20 mg) +  
C (AUC6) 
(n=3) 
A (40 mg) +  
C (AUC6) 
(n=9) 
 A (20 mg) +  
C (AUC6) +  
P (175 mg/m2) 
(n=7) 
A (20 mg) +  
C (AUC5) +  
P (175 mg/m2)  
(n=6) 
A (40 mg) +  
C (AUC5) +  
P (175 mg/m2)  
(n=5) 
A (30 mg) +  
C (AUC5) +  
P (175 mg/m2) 
(n=8)  
Patients evaluable for MTD 3 6  6 6 5 6 
Patients with a DLT 0 1  2 0 2 2 
DLTs leading to permanent 
discontinuation of study 
treatment 
0 0 2 0 0 0 
DLTs, n
Acneiform rasha
Mucositisb
Fatigue 
0 
0 
0 
1 
0 
0 
0 
1 
1 
0 
0 
0 
0 
1 
1 
0 
1 
0 
21 
Infectionc
Dehydration 
Diarrhea 
Febrile neutropenia/ 
neutropenic sepsisd
Renal impairment 
Small intestinal hemorrhage 
Stomatitis 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 
1 
1 
1 
1 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 
A/C afatinib plus carboplatin; A/C/P afatinib plus carboplatin plus paclitaxel; AUC5 area under the concentration–time curve of 5 mg/mL.min; AUC6 area 
under the concentration–time curve of 6 mg/mL.min; DLT dose-limiting toxicity; MTD maximum tolerated dose 
a Preferred term: dermatitis acneiform 
b Preferred term: mucosal inflammation 
c Clostridium difficile
d Includes one patient with febrile neutropenia and one patient with neutropenic sepsis 
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Table 3 Treatment-related AEs in at least 10% of total patients in the A/C arm 
A (20 mg) + C (AUC6) (n=3), 
n 
A (40 mg) + C (AUC6) (n=9), 
n 
Total (n=12), 
n (%) 
AEs All grades Grade 3a All grades Grade 3a All grades Grade 3a
Any AE 3 0 9 3 12 (100) 3 (25) 
Rash+ 2 0 7 1 9 (75) 1 (8) 
Fatigue 3 0 5 1 8 (67) 1 (8) 
Diarrhea 1 0 6 1 7 (58) 1 (8) 
Nausea/vomiting+ 1 0 5 0 6 (50) 0 
Anorexiab 1 0 3 0 4 (33) 0 
Thrombocytopenia 1 0 2 0 3 (25) 0 
Epistaxis 0 0 3 0 3 (25) 0 
Oropharyngeal pain 0 0 3 0 3 (25) 0 
Stomatitis 0 0 2 0 2 (17) 0 
Rhinitis 0 0 2 0 2 (17) 0 
Taste changec 1 0 1 0 2 (17) 0 
Dry skin 0 0 2 0 2 (17) 0 
Weight lossd 1 0 1 0 2 (17) 0 
Nasal inflammation 0 0 2 0 2 (17) 0 
A/C afatinib plus carboplatin; AE adverse event; AUC6 area under the concentration–time curve of 6 mg/mL.min 
a There were no treatment-related grade 4 or 5 events 
b Preferred term: decreased appetite 
23 
c Preferred term: dysgeusia 
d Preferred term: weight decreased 
+ = grouped term (rash included reported preferred terms of folliculitis, cellulitis, dermatitis acneiform and rash; nausea/vomiting included reported preferred 
terms of nausea and vomiting) 
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Table 4 Treatment-related AEs in at least 10% of total patients in the A/C/P arm 
A (20 mg) +  
C (AUC6) +  
P (175 mg/m2)  
(n=7),  
n 
A (20 mg) +  
C (AUC5) +  
P (175 mg/m2)
(n=6),  
n 
A (40 mg) +  
C (AUC5) +  
P (175 mg/m2) 
(n=5),  
n 
A (30 mg) +  
C (AUC5) +  
P (175 mg/m2) 
(n=8),  
n 
Total  
(n=26),  
n (%) 
AEs All grades Grade 3a All grades Grade 3a All grades Grade 3a All grades Grade 3a All grades Grade 3a
Any AE 7 3 6 2 5 4 7 3 25 (96) 12 (46) 
Diarrhea 6 1 6 0 5 0 6 0 23 (88) 1 (4) 
Rash+ 2 0 5 0 5 0 7 0 19 (73) 0 
Fatigue 5 1 4 0 5 2 4 0 18 (69) 3 (12) 
Mucositisb 3 1 2 0 3 1 4 2 12 (46) 4 (15) 
Anorexiac 4 0 1 0 3 0 2 0 10 (38) 0 
Dry skin 2 0 2 0 1 0 3 0 8 (31) 0 
Nausea/vomiting+ 4 0 0 0 1 0 3 0 8 (31) 0 
Stomatitis 0 0 3 1 3 0 1 1 7 (27) 2 (8) 
Thrombocytopenia 2 2 2 2 1 0 1 0 6 (23) 4 (15) 
Peripheral neuropathy 1 0 2 0 0 0 3 0 6 (23) 0 
Abdominal pain 4 0 0 0 1 0 1 0 6 (23) 0 
Neutropenia 1 1 3 2 1 1 0 0 5 (19) 4 (15) 
Epistaxis 2 0 1 0 1 0 1 0 5 (19) 0 
Nasal inflammation 0 0 2 0 3 0 0 0 5 (19) 0 
Alopecia 1 0 1 0 2 0 1 0 5 (19) 0 
25 
Arthralgia 1 0 1 0 1 0 2 0 5 (19) 0 
Taste changed 1 0 0 0 1 0 2 0 4 (15) 0 
Constipation 1 0 1 0 1 0 1 0 4 (15) 0 
Dyspepsia 2 0 0 0 0 0 2 0 4 (15) 0 
Myalgia 1 0 3 0 0 0 0 0 4 (15) 0 
Palmar-plantar 
erythrodysesthesia 
syndrome 
0 0 1 0 0 0 2 0 3 (12) 0 
A/C/P afatinib plus carboplatin plus paclitaxel; AE adverse event; AUC5 area under the concentration–time curve of 5 mg/mL.min; AUC6 area under the 
concentration–time curve of 6 mg/mL.min 
a There were no treatment-related grade 4 or 5 events 
b Preferred term: mucosal inflammation 
c Preferred term: decreased appetite 
d Preferred term: dysgeusia 
+ = grouped term (rash included reported preferred terms of rash, rash erythematous, rash pustular, dermatitis acneiform, skin fissures, blister and dermatitis; 
nausea/vomiting included reported preferred terms of nausea and vomiting) 
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Table 5 Pharmacokinetic parameters for carboplatin (measured as total platinum) and paclitaxel in the presence and absence of afatinib at the 
RP2D 
A (40 mg) + C (AUC6) A (20 mg) + C (AUC5) + P (175 mg/m2) 
Cycle 1 (– afatinib) Cycle 2 (+ afatinib) Cycle 1 (– afatinib) Cycle 2 (+ afatinib)  
gMean gCV, % gMean gCV, % gMean gCV, % gMean gCV, % 
Afatinib 
AUCƮ, ss, ng•h/mL - n=3a - n=7c
465 91.8 326 60.4 
Cmax,ss ng/mL - n=3 - n=7 
44.2 9.76 18.3 52.6 
Total platinum 
AUC0–24, ng•h/mL n=9 n=6a n=5b n=8c
76,800 16.9 75,700 23.6 69,700 12.4 65,400 20.9 
Cmax. ng/mL n=9 n=6 n=5 n=8 
21,100 31.0 19,600 26.8 16,200 22.9 17,800 15.8 
Paclitaxel 
AUC0–23, ng•h/mL - - n=5b n=8c
10,400 21.8 10,700 32.2 
Cmax, ng/mL - - n=5 n=8 
3710 23.4 3620 50.9 
A afatinib; AE adverse event; AUC0–23 area under the concentration–time curve of the analyte in plasma over 0–23 h; AUC0–24 area under the concentration–
time curve of the analyte in plasma over 0–24 h; AUCƮ,ss area under the concentration–time curve of the analyte in plasma over a dosing interval, tau, at 
steady state; AUC5 area under the concentration–time curve of 5 mg/mL.min; AUC6 area under the concentration–time curve of 6 mg/mL.min; C carboplatin; 
27 
Cmax maximum measured concentration of the analyte in plasma; Cmax, ss Cmax at steady state; gCV geometric coefficient of variation; gMean geometric mean; 
P paclitaxel; PK pharmacokinetic; RP2D recommended phase II dose 
aSome patients entered into the A (40 mg) + C (AUC6) cohort were not included in PK analyses in Cycle 2 due to AEs leading to treatment discontinuation, 
insufficient data availability for accurate PK evaluation or time violations in PK sampling. 
bOne patient entered into the A (20 mg) + C (AUC5) + P (175 mg/m2) cohort was not included in PK analyses in Cycle 1. 
cAdditional patients who received A (30 mg) + C (AUC5) + P (175 mg/m2) in Cycle 1 were subsequently moved to the A (20 mg) + C (AUC5) + P (175 mg/m2) 
dose cohort for Cycle 2 and were included in the PK analyses. 
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Figure caption 
Fig. 1 Dose escalation schema and incidence of DLTs in the A/C arm (a) and the A/C/P arm 
(b) 
A20 + C6 afatinib 20 mg/day + carboplatin at a dose targeting an area under the concentration–time 
curve of 6 mg/mL.min; A40 + C6 afatinib 40 mg/day + carboplatin at a dose targeting an area under 
the concentration–time curve of 6 mg/mL.min; A20 + P175 + C5 afatinib 20 mg/day + paclitaxel 175 
mg/m2 + carboplatin at a dose targeting an area under the concentration–time curve of 5 mg/mL.min; 
A20 + P175 + C6 afatinib 20 mg/day + paclitaxel 175 mg/m2 + carboplatin at a dose targeting an area 
under the concentration–time curve of 6 mg/mL.min; A30 + P175 + C5 afatinib 30 mg/day + paclitaxel 
175 mg/m2 + carboplatin at a dose targeting an area under the concentration–time curve of 5 
mg/mL.min; A40 + P175 + C5 afatinib 40 mg/day + paclitaxel 175 mg/m2 + carboplatin at a dose 
targeting an area under the concentration–time curve of 5 mg/mL.min; A afatinib; C carboplatin; DLT
dose-limiting toxicity; MTD maximum tolerated dose; P paclitaxel. 
